Optimized Expression Condition of CIDRα-PfEMP1 Recombinant Protein Production in Escherichia coli BL21(DE3): A Step to Develop Malaria Vaccine Candidate

Advances and challenges in recombinant protein expression in Escherichia coli

down regulation of acka-pta pathway in escherichia coli bl21 (de3): a step toward optimized recombinant protein expression system

materials and methods: in order to achieve this, recombinant plasmid harboring antisense sequences targeting both of pta and acka was assembled, after transfecting to the cells, its effects on the cell growth and acetate accumulation in the minimal media was assessed and compared with the control, the plasmid without antisense cassette, in presence and absence of iptg in escherichia coli bl21 (...

Production of specific IgY antibody to the recombinant FanC protein produced in Escherichia coli

Objective(s): Enterotoxigenic Escherichia coli (ETEC) strains are one of the primary causes of diarrhea in newborn calves and in humans, pigs, and sheep. IgY technology has been identified as a promising alternative to generating a mass amount of specific antibody for use in immunotherapy and immunodiagnostics. The purpose of this study was to produce specific antibody by egg yolk antibody (IgY...

Elevated Fis expression enhances recombinant protein production in Escherichia coli.

A genetic strategy to enhance recombinant protein production is discussed. A small DNA bending protein, Fis, which has been shown to activate rRNA synthesis upon a nutrient upshift, was overexpressed in E. coli strain W3110 carrying vector pUCR1. Overexpression of Fis during exponential growth was shown to activate rrn promoters to different extents. A 5-fold improvement in chloramphenicol acet...

Cloning, Expression and Characterization of Recombinant Exotoxin A-Flagellin Fusion Protein as a New Vaccine Candidate against Pseudomonas aeruginosa Infections

Background: Infections due to Pseudomonas aeruginosa are among the leading causes of morbidity and mortality in patients who suffer from impaired immune responses and chronic diseases such as cystic fibrosis. At present, aggressive antibiotic therapy is the only choice for management of P. aeruginosa infections, but emergence of highly resistant strains necessitated the development of novel alt...